Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-China state media says 18 more detained in GSK probe

Sat, 27th Jul 2013 11:18

BEIJING, July 27 (Reuters) - At least 18 more people havebeen detained in China in connection with a corruption scandalinvolving British drugmaker GlaxoSmithKline, state mediareported, giving more details on an investigation that hasrocked the company.

China's state radio reported late on Friday on its websitethat police in the central city of Zhengzhou had "recently held,in accordance with the law, 18 GlaxoSmithKline (China) employeesand some medical personnel".

It provided no details of the detentions nor say exactlywhen they happened.

The Zhengzhou police news department, reached by telephone,said they were "unaware of the situation" and declined tocomment further.

A GSK spokesman in London declined to comment on the report.

China's Ministry of Public Security said late on FridayGSK's former general manager for the country, Mark Reilly,currently in Britain, would return to China to cooperate in theinvestigation.

"The Ministry of Public Security welcomes GSK's position,and will provide necessary help to the work of the company'saudit team, and hopes that GSK China's operations and productionwill return to normal as soon as possible," it said.

Chinese police had earlier announced the detention of fourChinese GSK executives in connection with allegations that thedrugmaker funnelled up to 3 billion yuan ($489 million) totravel agencies to facilitate bribes to doctors and officials.

GSK has admitted that some Chinese executives appeared tohave broken the law but Chief Executive Andrew Witty said onWednesday that head office had no knowledge of the allegedwrongdoing.

The official Xinhua news agency said that certain GSKemployees were "suspected of offering bribes to doctors, askingthem to prescribe more drugs in order to grow sales volume, andin the meantime pushing up drug prices".

"PUSHING DOCTORS"

Xinhua cited an interview with a man surnamed Li, who itsaid was a regional sales manager for GSK responsible forselling respiratory drugs to more than 10 hospitals inZhengzhou, who gave details of how the corruption worked.

"They invited doctors to join high-end academic conferencesto help the practitioners increase influence in their fields.They also established good personal relations with doctors bycatering to their pleasures or offering them money, in order tomake them prescribe more drugs," Xinhua said.

"A 35-year-old female medical representative surnamed Wang,working under Li, said she entered doctors' offices to act astheir assistant, and meet their needs as much as possible, eventheir sexual desires," the news agency added.

"Wang said GSK China's executives already knew this, andsome executives gave clear directives to the sales department tooffer bribes to doctors with money or opportunities to attendacademic conferences."

However, many doctors got money even when the lectures didnot actually exist, Xinhua said.

"Wang just forged lecture materials in order to obtainreimbursements from the company," it added.

"According to Li and Wang, the company set the target ofraising drug sales by 30 percent annually in the last two years,and the target can only be achieved by pushing doctors toprescribe more if there are no increases in the number ofpatients," Xinhua reported.

GSK this week appointed one of its top European executivesas the new head of operations in China.

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.